| Identification | Back Directory | [Name]
MK-0969 | [CAS]
203321-88-4 | [Synonyms]
MK-0969
J104135
J-104135
J 104135
Benzeneacetamide, N-[1-[(6-amino-2-pyridinyl)methyl]-4-piperidinyl]-α-[(1R)-3,3-difluorocyclopentyl]-α-hydroxy-, (αR)- | [Molecular Formula]
C24H30F2N4O2 | [MOL File]
203321-88-4.mol | [Molecular Weight]
444.53 |
| Chemical Properties | Back Directory | [Melting point ]
169-170 °C(Solv: hexane (110-54-3); chloroform (67-66-3)) | [Boiling point ]
650.6±55.0 °C(Predicted) | [density ]
1.30±0.1 g/cm3(Predicted) | [pka]
12.38±0.29(Predicted) |
| Hazard Information | Back Directory | [Uses]
MK-0969 is a M3 antagonist. MK-0969 can be used for research about chronic obstructive pulmonary disease and urinary incontinence[1][2]. | [References]
[1] Sheng C, et al. Theoretical study on the mechanism of the benzaldehyde deoxyfluorination by sulfuryl fluoride and tetramethylammonium fluoride[J]. Journal of Physical Organic Chemistry, 2022, 35(8): e4389.
[2] Zhou L, et al., Impurity profile tracking for active pharmaceutical ingredients: case reports. J Pharm Biomed Anal. 2007 Jun 28;44(2):421-9. DOI:10.1016/j.jpba.2006.11.004 |
|
|